G R Devi

Summary

Affiliation: AVI BioPharma
Country: USA

Publications

  1. ncbi request reprint Differential effects of insulin-like growth factor (IGF)-binding protein-3 and its proteolytic fragments on ligand binding, cell surface association, and IGF-I receptor signaling
    G R Devi
    Department of Pediatrics, School of Medicine, Oregon Health Sciences University, Portland 97201 3042, USA
    Endocrinology 141:4171-9. 2000
  2. ncbi request reprint XIAP as target for therapeutic apoptosis in prostate cancer
    Gayathri R Devi
    Cancer and Endocrine Program, AVI BioPharma, Inc, Corvallis, Oregon 97333, USA
    Drug News Perspect 17:127-34. 2004
  3. ncbi request reprint Resistance to chemotherapeutic drugs overcome by c-Myc inhibition in a Lewis lung carcinoma murine model
    Derek C Knapp
    AVI BioPharma Inc, Corvallis, OR 97333, USA
    Anticancer Drugs 14:39-47. 2003
  4. ncbi request reprint Inhibition of human chorionic gonadotropin beta-subunit modulates the mitogenic effect of c-myc in human prostate cancer cells
    Gayathri R Devi
    AVI BioPharma, Corvallis, Oregon 97333, USA
    Prostate 53:200-10. 2002
  5. ncbi request reprint Prostate cancer: status of current treatments and emerging antisense-based therapies
    Gayathri R Devi
    AVI BioPharma Inc, Corvallis, OR 97333, USA
    Curr Opin Mol Ther 4:138-48. 2002
  6. ncbi request reprint Insulin-like growth factor binding protein-3 induces early apoptosis in malignant prostate cancer cells and inhibits tumor formation in vivo
    Gayathri R Devi
    Department of Pediatrics, School of Medicine, Oregon Health Sciences University, Portland, Oregon, USA
    Prostate 51:141-52. 2002
  7. ncbi request reprint Effect of IGFBP-3 on IGF- and IGF-analogue-induced insulin-like growth factor-I receptor (IGFIR) signalling
    G R Devi
    Department of Pediatrics, School of Medicine, Oregon Health Sciences University, Portland, OR 97201 3042, USA
    Growth Horm IGF Res 11:231-9. 2001
  8. ncbi request reprint In vivo bioavailability and pharmacokinetics of a c-MYC antisense phosphorodiamidate morpholino oligomer, AVI-4126, in solid tumors
    Gayathri R Devi
    AVI BioPharma, Inc, Corvallis, Oregon and Oregon Health and Science University Cancer Institute, Portland, Oregon, USA
    Clin Cancer Res 11:3930-8. 2005
  9. ncbi request reprint Neutrally charged phosphorodiamidate morpholino antisense oligomers: uptake, efficacy and pharmacokinetics
    Vikram Arora
    Research and Development, AVI BioPharma, Inc, USA
    Curr Pharm Biotechnol 5:431-9. 2004
  10. ncbi request reprint Androgen receptor down-regulation in prostate cancer with phosphorodiamidate morpholino antisense oligomers
    Yoo Joung Ko
    Cancer Biology Program, Hematology Oncology Division, Beth Israel Deaconess Medical Center, Harvard Medical School, 330 Brookline Avenue, Boston, MA 02215, USA
    J Urol 172:1140-4. 2004

Research Grants

Collaborators

Detail Information

Publications14

  1. ncbi request reprint Differential effects of insulin-like growth factor (IGF)-binding protein-3 and its proteolytic fragments on ligand binding, cell surface association, and IGF-I receptor signaling
    G R Devi
    Department of Pediatrics, School of Medicine, Oregon Health Sciences University, Portland 97201 3042, USA
    Endocrinology 141:4171-9. 2000
    ..However, unlike the (1-97)NH2-terminal fragment, the COOH-terminal fragments of IGFBP-3 retained their ability to associate with the cell surface, and this binding was competed by heparin, similar to intact IGFBP-3...
  2. ncbi request reprint XIAP as target for therapeutic apoptosis in prostate cancer
    Gayathri R Devi
    Cancer and Endocrine Program, AVI BioPharma, Inc, Corvallis, Oregon 97333, USA
    Drug News Perspect 17:127-34. 2004
    ..This review attempts to present an overview of the interaction between cell survival and death pathways, mechanism of XIAP action and recent studies supporting XIAP as an emerging therapeutic target...
  3. ncbi request reprint Resistance to chemotherapeutic drugs overcome by c-Myc inhibition in a Lewis lung carcinoma murine model
    Derek C Knapp
    AVI BioPharma Inc, Corvallis, OR 97333, USA
    Anticancer Drugs 14:39-47. 2003
    ..In conclusion, AVI-4126 potentiates the efficacy of chemotherapeutic drugs in a manner that is schedule dependent...
  4. ncbi request reprint Inhibition of human chorionic gonadotropin beta-subunit modulates the mitogenic effect of c-myc in human prostate cancer cells
    Gayathri R Devi
    AVI BioPharma, Corvallis, Oregon 97333, USA
    Prostate 53:200-10. 2002
    ..Human chorionic gonadotropin, a growth factor implicated in neoplasm, causes activation of c-myc through a G-protein-coupled pathway of signal transduction...
  5. ncbi request reprint Prostate cancer: status of current treatments and emerging antisense-based therapies
    Gayathri R Devi
    AVI BioPharma Inc, Corvallis, OR 97333, USA
    Curr Opin Mol Ther 4:138-48. 2002
    ..This review summarizes recent progress that has been made with the use of antisense technology with various chemistries to modify gene expression, a strategy that seems to hold great promise for prostate cancer therapy...
  6. ncbi request reprint Insulin-like growth factor binding protein-3 induces early apoptosis in malignant prostate cancer cells and inhibits tumor formation in vivo
    Gayathri R Devi
    Department of Pediatrics, School of Medicine, Oregon Health Sciences University, Portland, Oregon, USA
    Prostate 51:141-52. 2002
    ..Insulin-like growth factor binding protein (IGFBP-3) levels are significantly reduced in malignant prostate epithelial cells. In this study, we evaluated the role of endogenous IGFBP-3 on prostate cancer cell growth and tumorigenesis...
  7. ncbi request reprint Effect of IGFBP-3 on IGF- and IGF-analogue-induced insulin-like growth factor-I receptor (IGFIR) signalling
    G R Devi
    Department of Pediatrics, School of Medicine, Oregon Health Sciences University, Portland, OR 97201 3042, USA
    Growth Horm IGF Res 11:231-9. 2001
    ....
  8. ncbi request reprint In vivo bioavailability and pharmacokinetics of a c-MYC antisense phosphorodiamidate morpholino oligomer, AVI-4126, in solid tumors
    Gayathri R Devi
    AVI BioPharma, Inc, Corvallis, Oregon and Oregon Health and Science University Cancer Institute, Portland, Oregon, USA
    Clin Cancer Res 11:3930-8. 2005
    ..Data from both human studies indicated similar plasma concentration-time profile. These studies show PMO bioavailability in tumor tissue and establish the feasibility of using PMO targeting specific genes in human cancer clinical trials...
  9. ncbi request reprint Neutrally charged phosphorodiamidate morpholino antisense oligomers: uptake, efficacy and pharmacokinetics
    Vikram Arora
    Research and Development, AVI BioPharma, Inc, USA
    Curr Pharm Biotechnol 5:431-9. 2004
    ..This review will summarize the preclinical studies with PMOs on the road to their development as therapeutic agents with particular emphasis on in vivo biodistribution and pharmacokinetics...
  10. ncbi request reprint Androgen receptor down-regulation in prostate cancer with phosphorodiamidate morpholino antisense oligomers
    Yoo Joung Ko
    Cancer Biology Program, Hematology Oncology Division, Beth Israel Deaconess Medical Center, Harvard Medical School, 330 Brookline Avenue, Boston, MA 02215, USA
    J Urol 172:1140-4. 2004
    ..In this study we evaluated a novel antisense phosphorodiamidate morpholino oligomer (PMO) targeting the translational start site of AR mRNA in vitro and in vivo in a PCa xenograft and murine prostate...
  11. ncbi request reprint X-linked inhibitor of apoptosis protein inhibition induces apoptosis and enhances chemotherapy sensitivity in human prostate cancer cells
    Adams Amantana
    AVI BioPharma, Inc, 4575 SW Research Way, Suite 200, Corvallis, OR 97333, USA
    Mol Cancer Ther 3:699-707. 2004
    ..In conclusion, abrogation of XIAP expression is essential for therapeutic apoptosis and enhanced chemotherapy sensitization in androgen-refractory prostate cancer cells...
  12. ncbi request reprint A novel antisense inhibitor of MMP-9 attenuates angiogenesis, human prostate cancer cell invasion and tumorigenicity
    Carla A London
    AVI BioPharma Inc, 4575 SW Research Way, Suite 200, Corvallis, Oregon 97333, USA
    Cancer Gene Ther 10:823-32. 2003
    ..These data establish the feasibility of developing a site-directed, nontoxic antisense therapeutic agent for inhibiting local invasion and metastasis...
  13. ncbi request reprint Efficacy of antisense morpholino oligomer targeted to c-myc in prostate cancer xenograft murine model and a Phase I safety study in humans
    Patrick L Iversen
    AVI BioPharma Inc, Corvallis, Oregon 97333, USA
    Clin Cancer Res 9:2510-9. 2003
    ....
  14. ncbi request reprint c-MYC antisense phosphosphorodiamidate morpholino oligomer inhibits lung metastasis in a murine tumor model
    Harmanjatinder S Sekhon
    Oregon Health and Sciences University, Portland, OR, USA
    Lung Cancer 60:347-54. 2008
    ..The present study evaluates AVI-4126 on the development of lung metastasis in the LLC1 syngeneic murine tumor model. Further, this is the first study to show in vivo mis-splicing of c-MYC post-AVI-4126 treatment...

Research Grants2

  1. Inhibition of Androgen Receptor to treat Prostate Cancer
    Gayathri Devi; Fiscal Year: 2003
    ..Based on these data, future pharmacokinetic and toxicology animal studies will allow proceeding to human phase I testing in a timely and efficient manner. ..
  2. Antisense Morpholino Oligomers to Treat Retinopathy
    Gayathri Devi; Fiscal Year: 2003
    ..The primary goal of this grant is to identify the optimal antisense alphav PMO, dose and schedule that maximally decreases alpha V expression and inhibits retinopathy of prematurity. ..